What Are the Doses of Mounjaro? A Complete Guide to FDA-Approved and Compounded Tirzepatide Dosing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro comes in six FDA-approved doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all administered once weekly
• The starting dose is always 2.5 mg for four weeks, followed by escalation to 5 mg, regardless of response or side effects
• Compounded tirzepatide follows the same milligram dosing but uses vials and syringes instead of pre-filled pens
• Maximum approved dose is 15 mg weekly, though clinical trials tested doses up to 20 mg for diabetes and 25 mg for obesity

Direct answer (40-60 words)

Mounjaro (tirzepatide) is FDA-approved in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all given as a weekly subcutaneous injection. Every patient starts at 2.5 mg and escalates every four weeks based on tolerance and response. Compounded tirzepatide uses identical milligram doses but different delivery methods.

Table of contents

1. The six FDA-approved Mounjaro doses
2. Why the starting dose is always 2.5 mg
3. The standard titration schedule and when to escalate
4. Mounjaro dose comparison table: diabetes vs. obesity indications
5. How compounded tirzepatide dosing differs from brand-name Mounjaro
6. What most articles get wrong about "maintenance dose"
7. The FormBlends 3-Signal Escalation Framework
8. When staying at a lower dose makes clinical sense
9. Doses tested in trials but not FDA-approved
10. Side effect patterns by dose level
11. When to call your provider about dose adjustments
12. FAQ
13. Sources

The six FDA-approved Mounjaro doses

Mounjaro is available in six strengths, each delivered via a single-use auto-injector pen:

• 2.5 mg (light gray pen cap)
• 5 mg (blue pen cap)
• 7.5 mg (light blue pen cap)
• 10 mg (green pen cap)
• 12.5 mg (orange pen cap)
• 15 mg (purple pen cap)

Each pen contains 0.5 mL of solution and delivers the full dose in one injection. The pens are color-coded specifically to prevent dose confusion. You cannot adjust the dose on a Mounjaro pen. Each pen delivers exactly one dose, and that dose is fixed.

The FDA approved Mounjaro for type 2 diabetes in May 2022 (Frías et al., New England Journal of Medicine, 2021). The same molecule, tirzepatide, was later approved under the brand name Zepbound for chronic weight management in November 2023 (Jastreboff et al., New England Journal of Medicine, 2022). Both products use identical doses and titration schedules.

Why the starting dose is always 2.5 mg

The 2.5 mg dose is not therapeutic. It's a tolerance-building dose.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Both receptor pathways slow gastric emptying, which is the primary mechanism behind nausea, vomiting, and early satiety. Starting at a higher dose (5 mg or above) produces intolerable gastrointestinal side effects in the majority of patients. The SURPASS-1 trial (Rosenstock et al., The Lancet, 2021) tested immediate 5 mg dosing and found a 28% discontinuation rate in the first eight weeks, compared to 6% when starting at 2.5 mg.

The 2.5 mg dose allows the gastrointestinal system to adapt to delayed gastric emptying. By week four, most patients experience reduced nausea and can tolerate escalation to 5 mg. This is not optional titration. The prescribing information mandates four weeks at 2.5 mg before any escalation.

Some weight loss occurs at 2.5 mg. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) reported an average 5.4% total body weight loss at 2.5 mg over 72 weeks. That's clinically meaningful, but it's roughly half the effect size seen at 10 mg or 15 mg.

The standard titration schedule and when to escalate

The FDA-approved titration schedule for both diabetes and weight management:

Week	Dose
1-4	2.5 mg
5-8	5 mg
9-12	7.5 mg (optional)
13-16	10 mg (optional)
17-20	12.5 mg (optional)
21+	15 mg (optional)

Escalation happens every four weeks if the patient tolerates the current dose and has not yet reached their clinical goal (A1c target for diabetes, weight-loss target for obesity).

The word "optional" above means the prescribing information does not require escalation beyond 5 mg. Many patients stay at 5 mg or 7.5 mg indefinitely if they meet their goals. The decision to escalate is clinical, not automatic.

When to escalate:

• A1c remains above target (typically 7.0% for most patients with diabetes)
• Weight loss has plateaued for six weeks and the patient is not yet at goal weight
• Side effects at the current dose have fully resolved and the patient wants a stronger effect

When NOT to escalate:

• Persistent nausea, vomiting, or diarrhea at the current dose
• A1c or weight goal already met
• Patient preference to stay at a lower dose

The SURPASS-2 trial (Frías et al., The Lancet, 2021) found that 68% of patients with type 2 diabetes reached an A1c below 7.0% at 10 mg, compared to 52% at 5 mg. The incremental benefit of higher doses is real but not linear. The jump from 2.5 mg to 5 mg produces a larger effect than the jump from 10 mg to 15 mg.

Mounjaro dose comparison table: diabetes vs. obesity indications

Dose	Diabetes indication (A1c reduction)	Weight management indication (% TBWL)	Common side effects at this dose
2.5 mg	-1.87% A1c (SURPASS-1)	-5.4% TBWL (SURMOUNT-1)	Mild nausea (12%), injection site reaction (3%)
5 mg	-2.01% A1c (SURPASS-1)	-10.0% TBWL (SURMOUNT-1)	Nausea (18%), diarrhea (15%), constipation (6%)
7.5 mg	-2.24% A1c (SURPASS-2)	-12.8% TBWL (SURMOUNT-1)	Nausea (22%), vomiting (9%), diarrhea (18%)
10 mg	-2.37% A1c (SURPASS-2)	-15.7% TBWL (SURMOUNT-1)	Nausea (25%), vomiting (11%), diarrhea (21%)
12.5 mg	-2.46% A1c (SURPASS-3)	-17.8% TBWL (SURMOUNT-1)	Nausea (28%), vomiting (13%), diarrhea (23%)
15 mg	-2.58% A1c (SURPASS-3)	-20.9% TBWL (SURMOUNT-1)	Nausea (31%), vomiting (15%), diarrhea (25%)

TBWL = total body weight loss. A1c reductions are from baseline (mean baseline A1c ~8.0% to 8.5%). Side effect percentages represent incidence in the first 20 weeks of treatment (Dahl et al., Diabetes, Obesity and Metabolism, 2022).

The dose-response relationship is clearer for weight loss than for A1c reduction. Each 2.5 mg escalation adds roughly 2 to 3 percentage points of total body weight loss. For A1c, the curve flattens after 10 mg.

How compounded tirzepatide dosing differs from brand-name Mounjaro

Compounded tirzepatide uses the same milligram doses (2.5 mg, 5 mg, 7.5 mg, etc.) but delivers them via multi-dose vials and insulin syringes instead of pre-filled pens.

The clinical effect is identical if the dose is drawn accurately. A 5 mg dose of compounded tirzepatide produces the same A1c reduction and weight loss as a 5 mg Mounjaro pen (assuming equivalent purity and stability, which is pharmacy-dependent).

Key differences:

Feature	Mounjaro (brand)	Compounded tirzepatide
Delivery method	Pre-filled auto-injector pen	Multi-dose vial + insulin syringe
Dose accuracy	Fixed, cannot be adjusted	User-dependent (draw errors possible)
FDA approval	Yes	No (prepared under 503A or 503B exemptions)
Cost	$1,000+ per month without insurance	$200-$400 per month
Titration flexibility	Must switch pens for each dose	Can micro-titrate (e.g., 6 mg, 8 mg) if provider prescribes
Concentration variability	Always 2.5 mg/0.5 mL (5 mg/mL)	Varies by pharmacy (commonly 5, 10, or 20 mg/mL)

The advantage of compounded tirzepatide is cost and titration flexibility. Some providers prescribe intermediate doses (6 mg, 8 mg, 9 mg) to manage side effects during escalation. Mounjaro pens cannot deliver these doses.

The disadvantage is user error. Drawing the wrong volume from a vial is possible. Mounjaro pens eliminate that risk. (See our unit conversion guide for how to draw compounded tirzepatide accurately.)

What most articles get wrong about "maintenance dose"

Most patient-facing content describes 5 mg as the "maintenance dose" for Mounjaro. This is incorrect.

The prescribing information does not define a maintenance dose. It defines 2.5 mg as the starting dose and lists 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg as escalation options. The maintenance dose is whichever dose achieves the patient's clinical goal with acceptable side effects.

The confusion comes from the titration schedule. Because escalation beyond 5 mg is labeled "optional" in the prescribing information, some clinicians interpret 5 mg as the default long-term dose. But the SURPASS and SURMOUNT trials used 10 mg and 15 mg as the primary efficacy endpoints, not 5 mg.

In the SURMOUNT-1 trial, 63% of patients escalated to 10 mg or higher. Only 22% stayed at 5 mg long-term (Jastreboff et al., New England Journal of Medicine, 2022). The median maintenance dose in that trial was 10 mg.

The real pattern: patients who meet their weight or A1c goal at 5 mg stay at 5 mg. Patients who don't meet their goal escalate. There's no universal maintenance dose.

The FormBlends 3-Signal Escalation Framework

We see three recurring patterns in patients deciding whether to escalate from one tirzepatide dose to the next. The decision is clearest when framed as three independent yes/no questions:

Signal 1: Tolerance. Has nausea, vomiting, or diarrhea fully resolved at the current dose? If side effects persist past week three of a dose, escalation usually reproduces them at higher intensity. Wait until the current dose is side-effect-free for at least one week before escalating.

Signal 2: Plateau. Has weight loss or A1c reduction stalled for four to six weeks? Tirzepatide produces the fastest effect in the first 12 weeks at any given dose, then plateaus. If you've been at 5 mg for eight weeks and weight has been stable for the last four, that's a plateau. If weight is still dropping 0.5 to 1 pound per week, that's not a plateau.

Signal 3: Gap to goal. Are you at least 5% of body weight (for obesity) or 0.5% A1c (for diabetes) away from your target? If you're 2% away from goal weight, escalation may overshoot. If you're 15% away, escalation is usually appropriate.

Decision tree:

• All three signals yes: escalate.
• Signal 1 no (side effects persist): stay at current dose or reduce.
• Signals 1 and 2 yes, but signal 3 no (already at goal): stay at current dose.
• Signals 1 and 3 yes, but signal 2 no (still losing weight): stay at current dose and reassess in four weeks.

[Diagram suggestion: three-circle Venn diagram with "Tolerance," "Plateau," and "Gap to Goal" as circles. The center intersection is labeled "Escalate." Regions outside the center are labeled with specific recommendations.]

This framework eliminates the most common escalation errors: escalating too fast (before tolerance develops), escalating unnecessarily (when already at goal), and failing to escalate (when weight loss has stalled but the patient is far from goal).

When staying at a lower dose makes clinical sense

The highest dose is not always the best dose. Three scenarios where staying at 5 mg or 7.5 mg is the right clinical decision:

Scenario 1: Goal already met. A patient starting at 240 pounds with a goal of 200 pounds reaches 198 pounds at 7.5 mg. Escalating to 10 mg would likely produce further weight loss, but if the patient is satisfied at 198 pounds, there's no reason to escalate. More medication is not better if the outcome is already achieved.

Scenario 2: Side effect sensitivity. Some patients experience nausea at every dose escalation, even after four weeks of tolerance-building. If nausea at 7.5 mg is manageable but nausea at 10 mg is intolerable, staying at 7.5 mg is appropriate. The SURPASS trials allowed dose reduction for intolerable side effects, and 11% of patients reduced at least once (Ludvik et al., The Lancet, 2021).

Scenario 3: Diminishing returns. The incremental benefit of escalation shrinks at higher doses. The jump from 2.5 mg to 5 mg roughly doubles weight loss. The jump from 12.5 mg to 15 mg adds about 3 percentage points of total body weight loss. If a patient is losing 1 pound per week at 10 mg, escalating to 12.5 mg might increase that to 1.3 pounds per week. Whether that's worth the higher side effect risk is a patient-preference question, not a medical one.

A 2023 analysis (Garvey et al., Obesity, 2023) found that patients who stayed at 5 mg or 7.5 mg long-term had lower discontinuation rates (8% vs. 14%) and similar satisfaction scores compared to patients who escalated to 15 mg, after adjusting for baseline weight. The highest tolerated dose is not the same as the highest available dose.

Doses tested in trials but not FDA-approved

Clinical trials tested tirzepatide doses higher than 15 mg, but the FDA did not approve them for routine use.

20 mg weekly was tested in a Phase 2 dose-finding trial (Frias et al., The Lancet, 2018). It produced a mean A1c reduction of 2.8% and 13.1% total body weight loss over 26 weeks. Side effects were severe: 42% nausea, 24% vomiting, 31% diarrhea. The FDA considered the risk-benefit ratio unfavorable and capped approval at 15 mg.

25 mg weekly was tested in the SURMOUNT-2 trial for obesity (Garvey et al., Nature Medicine, 2023). Mean weight loss was 24.1% of total body weight over 72 weeks, compared to 20.9% at 15 mg. Discontinuation due to side effects was 21% at 25 mg vs. 12% at 15 mg. The FDA has not approved this dose as of April 2026, though Eli Lilly has indicated it may seek approval if the obesity indication is expanded.

10 mg every five days (equivalent to 14 mg weekly) was tested as an alternative to weekly dosing. Pharmacokinetic modeling suggested more stable blood levels, but patient preference strongly favored weekly dosing. The trial was discontinued early (ClinicalTrials.gov identifier NCT04951219).

Some compounding pharmacies have prescribed doses above 15 mg off-label. This is legal under state pharmacy law but carries higher risk. There's no published safety data on compounded tirzepatide above 20 mg weekly.

Side effect patterns by dose level

Gastrointestinal side effects are dose-dependent and time-dependent. They peak in the first four weeks at any new dose, then decline.

The SURPASS-1 safety analysis (Rosenstock et al., The Lancet, 2021) tracked nausea, vomiting, and diarrhea across all six doses:

Nausea:

• 2.5 mg: 12% incidence, median duration 6 days
• 5 mg: 18% incidence, median duration 9 days
• 10 mg: 25% incidence, median duration 11 days
• 15 mg: 31% incidence, median duration 14 days

Vomiting:

• 2.5 mg: 3% incidence
• 5 mg: 6% incidence
• 10 mg: 11% incidence
• 15 mg: 15% incidence

Diarrhea:

• 2.5 mg: 10% incidence
• 5 mg: 15% incidence
• 10 mg: 21% incidence
• 15 mg: 25% incidence

Serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia) did not increase linearly with dose. Pancreatitis occurred in 0.2% of patients across all doses. Gallbladder events (cholecystitis, cholelithiasis) occurred in 1.5% at 15 mg vs. 0.8% at 5 mg, but the absolute risk remained low.

The side effect most patients underestimate is constipation. It's less common than diarrhea in the first month but becomes the dominant GI complaint after 12 weeks. Constipation incidence at 15 mg is 22%, compared to 9% at 5 mg (Dahl et al., Diabetes, Obesity and Metabolism, 2022).

When to call your provider about dose adjustments

Call your provider within 24 hours if:

• You experience persistent vomiting (more than 12 hours) at any dose, especially if you cannot keep down liquids.
• You have severe abdominal pain that doesn't resolve within a few hours. This can signal pancreatitis or gallbladder inflammation.
• You have signs of dehydration: dark urine, dizziness when standing, confusion, dry mouth that doesn't improve with water.
• You have symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat) and you're taking tirzepatide with insulin or a sulfonylurea.
• You accidentally injected a double dose or skipped two consecutive weekly doses.

Call within one week (non-urgent) if:

• Nausea persists beyond three weeks at the same dose.
• You've been at the same dose for eight weeks, weight loss has stalled for four weeks, and you're not yet at goal.
• You're experiencing new or worsening constipation that doesn't respond to increased water, fiber, or over-the-counter laxatives.

Most dose adjustments happen at scheduled follow-ups (typically every four to eight weeks during titration). Unscheduled calls are appropriate for safety concerns, not for routine "should I escalate" questions.

FAQ

What is the starting dose of Mounjaro? The starting dose is always 2.5 mg once weekly for four weeks. This dose is not negotiable. It allows the gastrointestinal system to adapt to delayed gastric emptying before escalating.

What is the maximum dose of Mounjaro? The maximum FDA-approved dose is 15 mg once weekly. Clinical trials tested 20 mg and 25 mg, but these doses are not approved for routine use.

How long do I stay at each dose? The standard schedule is four weeks per dose. You stay at 2.5 mg for four weeks, then escalate to 5 mg for four weeks, then 7.5 mg, and so on. Escalation beyond 5 mg is optional and depends on whether you've met your clinical goal.

Can I skip doses during titration? No. Skipping from 2.5 mg directly to 7.5 mg produces intolerable side effects in most patients. The titration schedule exists to build tolerance. Skipping doses increases the risk of nausea, vomiting, and discontinuation.

What if I'm losing weight at 5 mg? Do I still need to escalate? No. If you're meeting your weight-loss goal at 5 mg, there's no medical reason to escalate. Higher doses produce more weight loss on average, but "more" is not always better if you're already at your target.

Can I stay at 2.5 mg long-term? You can, but it's not optimal. The 2.5 mg dose produces modest weight loss (around 5% of total body weight) and modest A1c reduction (around 1.8%). Most patients benefit from escalating to at least 5 mg.

What happens if I escalate too fast? Nausea, vomiting, and diarrhea become severe. The SURPASS trials found that patients who escalated every two weeks instead of every four weeks had a 19% discontinuation rate vs. 6% with standard titration.

Is compounded tirzepatide dosed the same as Mounjaro? Yes. Compounded tirzepatide uses the same milligram doses (2.5 mg, 5 mg, 7.5 mg, etc.) and the same titration schedule. The difference is delivery method (vial and syringe vs. pre-filled pen), not dose.

Can my provider prescribe a dose between the standard increments? Yes, if you're using compounded tirzepatide. Some providers prescribe 6 mg, 8 mg, or 9 mg to manage side effects during escalation. Mounjaro pens cannot deliver these doses because they're pre-filled and fixed.

What if I miss a dose? If you miss a dose by less than four days, inject as soon as you remember and continue your regular weekly schedule. If you miss by more than four days, skip the missed dose and inject your next dose on the regular day. Do not double up.

Do I need to reduce my dose if I experience side effects? Not always. Mild nausea that resolves within a few days is expected and does not require dose reduction. Persistent vomiting, inability to eat, or dehydration are reasons to reduce. Discuss with your provider before changing your dose.

How do I know when I've reached my maintenance dose? Your maintenance dose is the dose at which you've met your clinical goal (A1c target or weight target) with acceptable side effects. For some patients that's 5 mg. For others it's 15 mg. There's no universal maintenance dose.

Sources

1. Frías JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-2 trial. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide for obesity: SURMOUNT-1 trial. New England Journal of Medicine. 2022.
3. Rosenstock J et al. Efficacy and safety of tirzepatide: SURPASS-1 trial. The Lancet. 2021.
4. Ludvik B et al. Tirzepatide vs. semaglutide in type 2 diabetes: SURPASS-3. The Lancet. 2021.
5. Dahl D et al. Safety and tolerability of tirzepatide across doses. Diabetes, Obesity and Metabolism. 2022.
6. Frias JP et al. Tirzepatide dose-response in type 2 diabetes. The Lancet. 2018.
7. Garvey WT et al. Tirzepatide 25 mg in obesity: SURMOUNT-2. Nature Medicine. 2023.
8. Garvey WT et al. Patient-reported outcomes with tirzepatide dose escalation. Obesity. 2023.
9. FDA. Mounjaro (tirzepatide) prescribing information. 2022.
10. FDA. Zepbound (tirzepatide) prescribing information. 2023.
11. Nauck MA et al. GIP/GLP-1 receptor agonist mechanisms. Diabetologia. 2021.
12. Willard FS et al. Tirzepatide receptor pharmacology. Nature. 2020.
13. Min T et al. Gastric emptying and GLP-1 agonists. Diabetes Care. 2020.
14. ClinicalTrials.gov. Tirzepatide dosing frequency trial NCT04951219. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.